Need Assistance?

US & Canada:
+
UK: +

FAQs

Resources

Our Highlights

GMP Grade Efficient workshop for GMP production.
Optimal Prices Buying products on this site guarantees the best price!
Commercial Batches Independent GMP manufacturing suites that handle commercial batches
Prompt Delivery Warehouses in multiple cities to ensure timely delivery
Flexible Quantity Quantities available from milligrams to ton

Application Area

Nα-Boc-L-arginine hydrochloride hydrate

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Category

BOC-Amino Acids

Catalog number

BAT-002923

CAS number

35897-34-8

Molecular Formula

C11H22N4O4·HCl·H2O

Molecular Weight

328.80

IUPAC Name

(2S)-5-(diaminomethylideneamino)-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoic acid

Synonyms

Boc-L-Arg-OH HCl H2O; BOC-ARG-OH HCI; BOC-ARGININE; Nα-Boc-L-arginine Hydrochloride Monohydrate; BOC-ARG-OH; Boc-Arg-Ohhydrochloride

Appearance

White powder

Purity

≥ 99% (HPLC)

Density

1.28 g/cm3

Melting Point

110-127 °C

Storage

Store at 2-8 °C

InChI

InChI=1S/C11H22N4O4.ClH/c1-11(2,3)19-10(18)15-7(8(16)17)5-4-6-14-9(12)13;/h7H,4-6H2,1-3H3,(H,15,18)(H,16,17)(H4,12,13,14);1H/t7-;/m0./s1

InChI Key

HDELGKMVZYHPPB-FJXQXJEOSA-N

Canonical SMILES

CC(C)(C)OC(=O)NC(CCCN=C(N)N)C(=O)O.Cl

Nα-Boc-L-Arginine hydrochloride hydrate is a protected form of the amino acid arginine, commonly used in the field of biosciences. Here are some key applications of Nα-Boc-L-Arginine hydrochloride hydrate:

Peptide Synthesis: Nα-Boc-L-Arginine hydrochloride hydrate is widely used in solid-phase peptide synthesis as a building block. The Boc protection group on arginine allows for selective deprotection and coupling during peptide chain elongation. This ensures high yields and purity of the final peptide products, which are critical for various research and therapeutic applications.

Protein Modification: In protein engineering, Nα-Boc-L-Arginine hydrochloride hydrate can be used to introduce arginine residues into proteins. This is particularly useful for studying protein-protein interactions, enzyme activity, and structural stability. The incorporation of arginine residues can enhance protein solubility and folding, thereby facilitating functional and structural studies.

Pharmaceutical Research: Nα-Boc-L-Arginine hydrochloride hydrate is employed in the development of pharmaceuticals, particularly in the design of prodrugs. By modifying the arginine residue, researchers can improve the drug's stability, bioavailability, and targeting capabilities. This approach is useful for developing new therapeutics for a range of diseases, including cardiovascular disorders and cancer.

Biocatalysis: In the field of biocatalysis, Nα-Boc-L-Arginine hydrochloride hydrate serves as a substrate or intermediate in enzymatic reactions. Its protected form allows for controlled reactions, minimizing side products and enhancing reaction specificity. This is valuable in industrial biotechnology processes for the efficient production of amino acids, peptides, and other specialized biomolecules.

1. Bis{[amino-(iminium-yl)meth-yl]urea} tetra-kis-{2-[(di-methyl-amino)(iminium-yl)meth-yl]guanidine} di-μ6-oxido-tetra-μ3-oxido-tetra-deca-μ2-oxido-octa-oxidodeca-vanadium(V) tetra-hydrate

Aarón Pérez-Benítez, et al. IUCrdata. 2022 Jun 24;7(Pt 6):x220627. doi: 10.1107/S2414314622006277. eCollection 2022 Jun.

The title compound, (C4H12N5)4(C2H7N4O)2[V10O28]·4H2O, is a by-product obtained by reacting ammonium metavanadate(V), metformin hydro-chloride and acetic acid in the presence of sodium hypochlorite, at pH = 5. The crystal structure comprises a deca-vanadate(V) anion (V10O28)6- lying on an inversion centre in space group P , while cations and solvent water mol-ecules are placed in general positions, surrounding the anion, and forming numerous N-H⋯O and O-H⋯O hydrogen bonds. Metforminium (C4H12N5)+ and guanylurea (C2H7N4O)+ cations display the expected shape. Inter-estingly, in physiology the latter cation is known to be the main metabolite of the former one. The reported structure thus supports the role of sodium hypochlorite as an oxidizing reagent being able to degrade metformin hydro-chloride to form guanylurea.

2. Gateways to clinical trials

M Bayes, X Rabasseda, J R Prous Methods Find Exp Clin Pharmacol. 2006 Sep;28(7):451-95.

Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com This issue focuses on the following selection of drugs: A-007, A6, adalimumab, adenosine triphosphate, alefacept, alemtuzumab, AllerVax Ragweed, amphora, anakinra, angiotensin-(1-7), anidulafungin, apomine, aripiprazole, atomoxetine hydrochloride, avanafil; BAL-8557, becatecarin, bevacizumab, biphasic insulin aspart, BMS-188797, bortezomib, bosentan, botulinum toxin type B, brivudine; Calcipotriol/betamethasone dipropionate, caspofungin acetate, catumaxomab, certolizumab pegol, cetuximab, CG-0070, ciclesonide, cinacalcet hydrochloride, clindamycin phosphate/benzoyl peroxide, cryptophycin 52, Cypher; Dabigatran etexilate, darapladib, darbepoetin alfa, decitabine, deferasirox, desloratadine, dexanabinol, dextromethorphan/quinidine sulfate, DMF, drotrecogin alfa (activated), duloxetine hydrochloride; E-7010, edaravone, efalizumab, emtricitabine, entecavir, eplerenone, erlotinib hydrochloride, escitalopram oxalate, estradiol valerate/dienogest, eszopiclone, exenatide, ezetimibe; Fondaparinux sodium, fulvestrant; Gefitinib, gestodene, GYKI-16084; Hyaluronic acid, hydralazine hydrochloride/isosorbide dinitrate; Imatinib mesylate, indiplon, insulin glargine; Juzen-taiho-to; Lamivudine/zidovudine/abacavir sulfate, L-arginine hydrochloride, lasofoxifene tartrate, L-BLP-25, lenalidomide, levocetirizine, levodopa/carbidopa/entacapone, lexatumumab, lidocaine/prilocaine, lubiprostone, lumiracoxib; MAb-14.18, mitoquidone; Natalizumab, neridronic acid, neuradiab; Olpadronic acid sodium salt, omalizumab; p53-DC vaccine, parathyroid hormone (human recombinant), peginterferon alfa-2a, peginterferon alfa-2b, pemetrexed disodium, perifosine, pimecrolimus, prasterone, prasugrel, PRO-2000, Pseudostat; R24, rasburicase, RHAMM R3 peptide, rilonacept, rosuvastatin calcium, rotavirus vaccine, rufinamide; Sabarubicin hydrochloride, SHL-749, sirolimus-eluting stent, SLx-2101, sodium butyrate, sorafenib, SU-6668; TachoSil, tadalafil, taxus, tegaserod maleate, telbivudine, tenofovir disoproxil fumarate, teriparatide, tetramethylpyrazine, teverelix, tiotropium bromide, tipifarnib, tirapazamine, tolvaptan, TransvaxTM hepatitis C vaccine, treprostinil sodium; Valganciclovir hydrochloride, valsartan/amlodipine, vandetanib, vardenafil hydrochloride hydrate, vatalanib succinate, veglin, voriconazole; Yttrium 90 (90Y) ibritumomab tiuxetan; Zileuton, zotarolimus, zotarolimus-eluting stent.

3. Chloral hydrate as a sedating agent for neurodiagnostic procedures in children

Choong Yi Fong, Wei Kang Lim, Limin Li, Nai Ming Lai Cochrane Database Syst Rev. 2021 Aug 16;8(8):CD011786. doi: 10.1002/14651858.CD011786.pub3.

Background: This is an updated version of a Cochrane Review published in 2017. Paediatric neurodiagnostic investigations, including brain neuroimaging and electroencephalography (EEG), play an important role in the assessment of neurodevelopmental disorders. The use of an appropriate sedative agent is important to ensure the successful completion of the neurodiagnostic procedures, particularly in children, who are usually unable to remain still throughout the procedure. Objectives: To assess the effectiveness and adverse effects of chloral hydrate as a sedative agent for non-invasive neurodiagnostic procedures in children.